Ascentage Pharma Group International (AAPG) Liabilities and Shareholders Equity (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $558.8 million as the latest value for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 53.34% year-over-year to $558.8 million; the TTM value through Dec 2025 reached $1.3 billion, changed N/A, while the annual FY2025 figure was $551.5 million, 53.79% up from the prior year.
- Liabilities and Shareholders Equity hit $558.8 million in Q4 2025 for Ascentage Pharma Group International, up from $364.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $558.8 million in Q4 2025 and bottomed at $347.3 million in Q4 2023.
- Average Liabilities and Shareholders Equity over 3 years is $423.5 million, with a median of $364.4 million recorded in 2024.
- Year-over-year, Liabilities and Shareholders Equity grew 4.94% in 2024 and then skyrocketed 53.34% in 2025.
- Ascentage Pharma Group International's Liabilities and Shareholders Equity stood at $347.3 million in 2023, then grew by 4.94% to $364.4 million in 2024, then surged by 53.34% to $558.8 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $558.8 million, $364.4 million, and $347.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.